Sentences with phrase «of women with ovarian cancer»

Just 20 % of women with ovarian cancer are cured — meaning the illness never comes back — after undergoing surgery and chemo.

She estimates that about 50 percent of women with ovarian cancer have tumors with this type of tumor and would qualify for the trial, which needs about $ 2 million in philanthropic funding before it could begin.

Nearly 20 percent of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

«This would be an individualized treatment that could increase survival rates of some women with ovarian cancer.»

By the time of diagnosis the majority of women with ovarian cancer already have extensive spread of the disease which makes it difficult to treat by surgery or chemotherapy.

Not exact matches

Yet 20 % of women diagnosed with lung cancer each year — about 21,000 in 2010, roughly the same number as new cases of ovarian cancer — never smoked.

Therefore, the overwhelming majority of women who are diagnosed with ovarian cancer do not sue claiming that someone should have figured it out sooner.

Women for whom genetic testing is recommended are: women who are diagnosed with breast cancer under the age of 50, are of Ashkenazi ancestry, have bilateral breast cancer, have ovarian cancer, have triple negative breast cancer, or have 2 or more family members with breast caWomen for whom genetic testing is recommended are: women who are diagnosed with breast cancer under the age of 50, are of Ashkenazi ancestry, have bilateral breast cancer, have ovarian cancer, have triple negative breast cancer, or have 2 or more family members with breast cawomen who are diagnosed with breast cancer under the age of 50, are of Ashkenazi ancestry, have bilateral breast cancer, have ovarian cancer, have triple negative breast cancer, or have 2 or more family members with breast cancer.

Examples might include a 30 - year - old healthy woman without a family history of ovarian cancer wanting to have her ovaries removed to prevent such a cancer; a woman with fibroids wanting an experimental surgical treatment whose long - term effects are still unknown; or an 18 - year - old woman without children wanting a sterilization procedure.

For women who choose to breastfeed there are lower risks associated with breast and ovarian cancer, less chance of hip fractures and osteoporosis in later life, and the added benefit that it helps with getting back to their pre-baby weight.

Recent research demonstrates that lactating women have an earlier return to prepregnant weight, 41 delayed resumption of ovulation with increased child spacing,42 - 44 improved bone remineralization postpartum45 with reduction in hip fractures in the postmenopausal period, 46 and reduced risk of ovarian cancer47 and premenopausal breast cancer.48

Enabling women to breastfeed is also a public health priority because, on a population level, interruption of lactation is associated with adverse health outcomes for the woman and her child, including higher maternal risks of breast cancer, ovarian cancer, diabetes, hypertension, and heart disease, and greater infant risks of infectious disease, sudden infant death syndrome, and metabolic disease (2, 4).

Part of my mission is to share information about ovarian cancer with women in order to help them understand the risk factors, symptoms and precautions to promote early detection and reduce ovarian cancer related deaths.

For that reason, the American Cancer Society recommends annual MRI screenings only in women with a strong family history of breast or ovarian cCancer Society recommends annual MRI screenings only in women with a strong family history of breast or ovarian cancercancer.

Many doctors who no longer advise mammograms for most women younger than 50 continue to suggest them for those with a family history of breast or ovarian cancer.

In reality, it turns out that many women with high levels of CA 125 do not have ovarian cancer, and, conversely, many women with cancer do not have high levels of CA 125.

Thousands of women are living with ovarian cancer in Canada.

Among postmenopausal women, the women with the highest quartile of HEI - 2010 scores were 43 percent less likely to be diagnosed with ovarian cancer, and the women with the highest quartile AHEI - 2010 scores were 51 percent less likely to be diagnosed with ovarian cancer than the women in the lowest quartile.

Because ovarian cancer is relatively rare, occurring in approximately one out of every 2,500 women, a test with only 99 percent specificity would result in false - positive diagnoses for 25 women, leading to unnecessary and risky surgeries and procedures.

Researchers at the Georgia Institute of Technology collected blood from 44 women diagnosed with ovarian cancer at various stages, along with that from 50 healthy controls.

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United States.

But Weidhaas and Slack's studies showed how the KRAS - variant increases a woman's risk of ovarian cancer — more than 27 percent of women with this type of cancer carried the variant.

One patient, a 46 - year old woman, started the trial with stage 4 ovarian cancer — which generally has a very poor prognosis — following five prior courses of chemotherapy.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

«This study provided encouraging preliminary results for the use of RT in women with ovarian cancer.»

«What we've discovered will help clinicians to better treat women with ovarian cancer,» says Dr. Ben Tsang, senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa.

Women with a family history of two or more immediate family members (mother, sister, daughter) with breast or ovarian cancer or with a positive genetic test for mutations in the BRCA1 or BRCA2 genes may be advised to consider having both breasts removed, because they are at high risk of a new cancer developing in the other breast.

Those in the heaviest group, women with a BMI over 28, had only 52 percent the ovarian cancer incidence of recruits in the leanest group, those with a BMI of 23 and under.

An analysis of mutations in the BRCA1 and BRCA2 genes reveals that women with breast cancer and women with ovarian cancer harbored mutations in different regions of the genes.

They also found differences in the types of bacteria in the upper reproductive tracts of women with and without epithelial ovarian cancer.

In the Hereditary Ovarian Cancer Clinical Study, researchers from Canada, the United States, Poland, Norway, Austria, France, and Italy identified women with BRCA mutations from an international registry, 5,787 of whom completed questionnaires about their reproductive history, surgical history (including preventive oophorectomy and mastectomy), and hormone use.

After an average follow - up period of 5.6 years (with some women followed as long as 16 years), 186 women developed either ovarian, fallopian tube, or peritoneal cancer.

Researchers conducted an analysis that included nearly 10,000 women with the BRCA1 or BRCA2 genetic mutations to estimate the age - specific risk of breast or ovarian cancer for women with these mutations, according to a study published by JAMA.

During a median follow - up of 5 years, 426 women were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with contralateral breast cancer (cancer in the breast opposite to one previously diagnosed with cancer).

«Up to 50 percent of women with advanced - stage ovarian cancer could be cured with one treatment model, expert argues.»

Dr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cCancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cancercancer:

Up to half of women with advanced - stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late - stage ovarian cawomen with advanced - stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late - stage ovarian caWomen's College Research Institute, who calls for a new standard of treatment for women with late - stage ovarian cawomen with late - stage ovarian cancer.

If a woman with a strong family history of breast and ovarian cancers tests negative for the BRCA1 / 2 genes, that does not mean her relatives are not at risk, says Daly — her siblings could still carry the gene, or there could be additional genes present that predispose them to cancer that clinicians don't yet know how to test for.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

«For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Instiwomen have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Instiwomen with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research InstiWomen's College Research Institute.

More than 80 percent of women with advanced stage high - grade serous ovarian cancer experience relapses even after repeated surgeries and multiple rounds of chemotherapy, and this effective new approach to treat the disease could be a major step forward in preventing cancer from returning.

«At the moment, the way we assess women with ovarian cysts for the presence of cancer and select treatment lacks accuracy.

«Women with ovarian cancer gain extra months with addition of drug to standard chemotherapy.»

In 2014, the FDA approved bevacizumab with chemotherapies for the treatment of women with platinum - resistant, recurrent ovarian cancer.

When Lisbeth Ceriani, a 43 - year - old Massachusetts woman, was diagnosed with breast cancer last year, her doctors recommended that she undergo genetic testing to see if she carried mutations in the BRCA1 and BRCA2 genes that increase risk of breast and ovarian cancers.

Ten women underwent surgery based on their ultrasound exams, with four having invasive ovarian cancers, two having ovarian tumors of low malignant potential, one having endometrial cancer, and three having benign ovarian tumors.

The period of time before ovarian cancer recurred (called progression - free survival) improved by nearly 3.5 months with the additional drug (13.8 months compared with 10.4 months for the woman on chemotherapy alone).

«The results from our study are not practice - changing at this time; however, our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial in post-menopausal women with an average risk of developing ovarian cancer,» said Dr. Lu.

For women with ovarian cancer, a particularly deadly form of gynecologic cancer, even improvements in treatment outcomes have been elusive.

Tamara Minko, professor in the Ernest Mario School of Pharmacy, and Lorna Rodriguez, professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical School, say because there is not a good screening method for ovarian cancer, most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.